학술논문

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Document Type
Article
Source
In Annals of Oncology April 2017 28(4):855-861
Subject
Language
ISSN
0923-7534